Mayne Pharma | MYX - Ebit



金融业
股票价格
AUD
资产
AUD 1.14B
现金及等价物
AUD 110.07M
销售成本
AUD 43.74M
流动资产
AUD 460.59M
流动负债
AUD 313.94M
债务
AUD 38.82M
EBIT
AUD -16.2M
EBITDA
AUD 20.9M
员工
450
EPS每股收益
AUD -0.15
股本和储备
AUD 454.19M
销售毛利
AUD 86.13M
债务利息支出
AUD 1.2M
贷款资金
AUD 2.66M
市值
AUD 232.25M
净收入
AUD -103.68M
营业费用
AUD 103.54M
营业利润
AUD -3.3M
普通股股本
AUD 81.25M
税前利润
AUD -14.7M
销售收入
AUD 212.07M
销售和管理费用
AUD 54.8M
股票
AUD 74.63M
贸易债权人
AUD 30.25M
应收帐款人
AUD 193.22M


Ebit 更改 日
Ansell USD 146.5M 29.2M 2025-12
Avita Medical AUD -10.39M 1.72M 2025-12
Cochlear AUD 261.1M 13.9M 2025-12
CSL USD 2.64B 116M 2025-12
Healius AUD 23.7M 26M 2024-12
Integral Diagnostics AUD 24.99M 5.08M 2024-06
Medical Developments International AUD -36K 12.96M 2025-12
Nanosonics AUD 9.12M 422K 2025-12
Polynovo AUD 2.06M 1.18M 2025-12
Ramsay Health Care AUD 541.1M 20.7M 2025-12
ResMed USD 499.81M 2.22M 2026-03
Sigma Healthcare AUD 809K 13.76M 2024-12
Sonic Healthcare AUD 423.94M 80.3M 2024-12
Telix Pharmaceuticals AUD 8.04M 3.21M 2025-12